←Autism Spectrum Disorder

Study register · detail Prospektive Real-World-Registerstudie · Autism Spectrum Disorder · 2019

Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy

Bar-Lev Schleider et al. ·Scientific Reports Impact 4.4

Clear benefit GRADE Low 183 citations

Samplen = 188 Pat.

Duration6 months

EndpointPatient global assessment

Blindingn.a.

DesignProspektive Real-World-Registerstudie

Cannabinoidkombination

THC:CBD1:20

Routeoral

Key finding

About 84% of evaluable ASD patients showed moderate to significant symptom improvement after 6 months under CBD/THC oil.

Summary

Real-world analysis of n=188 ASD patients under medical cannabis (30% CBD + 1,5% THC oil) between 2015–2017. After 6 months, n=93 were evaluated: 30,1% significant improvement, 53,7% moderate improvement, 6,4% mild improvement. 25,2% reported at least one adverse event (most common: restlessness 6,6%). Cannabis well tolerated and safe in ASD.

PopulationChildren and adolescents with autism spectrum disorder (ASD), n=188 (93 evaluated after 6 months)

InterventionCannabis oil with 30% CBD and 1,5% THC, oral

Outcome83,8% of the assessed patients showed moderate to significant improvement in overall condition; 25,2% reported at least one adverse event (most common: restlessness 6,6%)

Confidence in the evidence

Low

The second of four GRADE levels, the effect estimate is of limited reliability.

Quality profile

Sample size ★★★★★

Blinding —

Effect size Clear benefit

Citations / year ★★★★★

Authors

Bar-Lev Schleider L, Mechoulam R, Saban N et al.

DOI 10.1038/s41598-018-37570-y↗

Design: Prospektive Real-World-Registerstudie

The impediment to action advances action. — Marcus Aurelius